File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/S1470-2045(15)00050-9
- Scopus: eid_2-s2.0-84937523736
- PMID: 26095784
- WOS: WOS:000357273600059
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
Title | Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial |
---|---|
Authors | |
Issue Date | 2015 |
Publisher | The Lancet Publishing Group. The Journal's web site is located at http://www.elsevier.com/locate/j.lancetoncol |
Citation | The Lancet Oncology, 2015, v. 16 n. 7, p. 859-870 How to Cite? |
Persistent Identifier | http://hdl.handle.net/10722/217268 |
ISSN | 2023 Impact Factor: 41.6 2023 SCImago Journal Rankings: 12.179 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Zhu, AX | - |
dc.contributor.author | Park, JO | - |
dc.contributor.author | Ryoo, BY | - |
dc.contributor.author | Yen, CJ | - |
dc.contributor.author | Poon, RTP | - |
dc.date.accessioned | 2015-09-18T05:54:30Z | - |
dc.date.available | 2015-09-18T05:54:30Z | - |
dc.date.issued | 2015 | - |
dc.identifier.citation | The Lancet Oncology, 2015, v. 16 n. 7, p. 859-870 | - |
dc.identifier.issn | 1470-2045 | - |
dc.identifier.uri | http://hdl.handle.net/10722/217268 | - |
dc.language | eng | - |
dc.publisher | The Lancet Publishing Group. The Journal's web site is located at http://www.elsevier.com/locate/j.lancetoncol | - |
dc.relation.ispartof | The Lancet Oncology | - |
dc.title | Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial | - |
dc.type | Article | - |
dc.identifier.email | Poon, RTP: poontp@hku.hk | - |
dc.identifier.authority | Poon, RTP=rp00446 | - |
dc.identifier.doi | 10.1016/S1470-2045(15)00050-9 | - |
dc.identifier.pmid | 26095784 | - |
dc.identifier.scopus | eid_2-s2.0-84937523736 | - |
dc.identifier.hkuros | 254801 | - |
dc.identifier.volume | 16 | - |
dc.identifier.issue | 7 | - |
dc.identifier.spage | 859 | - |
dc.identifier.epage | 870 | - |
dc.identifier.isi | WOS:000357273600059 | - |
dc.publisher.place | United Kingdom | - |
dc.identifier.issnl | 1470-2045 | - |